RT Journal Article
T1 Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.
A1 Neukam, Karin
A1 Mira, José A
A1 Collado, Antonio
A1 Rivero-Juárez, Antonio
A1 Monje-Agudo, Patricia
A1 Ruiz-Morales, Josefa
A1 Ríos, María José
A1 Merino, Dolores
A1 Téllez, Francisco
A1 Pérez-Camacho, Inés
A1 Gálvez-Contreras, María Carmen
A1 Rivero, Antonio
A1 Pineda, Juan A
K1 Hepatitis B crónica
K1 Bilirrubina
K1 Ciclohexanos
K1 Estudios de seguimiento
K1 Infecciones por VIH
K1 Inhibidores de proteasas
K1 ARN
K1 Inhibidores de la transcriptasa inversa
K1 Transaminasas
AB OBJECTIVETo assess the current frequency of ART-associated grade 3-4 transaminase elevations (TE) and grade 4 total bilirubin elevations (TBE) in HIV-infected patients with chronic hepatitis B and/or C, who start a new regimen of ART.PATIENTS AND METHODSA total of 192 pre-treated or treatment-naive HIV infected patients with HBV and/or HCV-coinfection who started ART in eight Southern Spanish centers from July/2011-December/2013, were followed for 12 months in this prospective study.RESULTSForty-one (21.4%) subjects had been naïve to ART, median (IQR) follow-up was 11.6 (5.6-12.9) months. The most frequently initiated NRTI were tenofovir/emtricitabine [49 patients (25.5%)]. Eighty-nine (46.4%) patients started a ritonavir-boosted protease inhibitor and 77 (40.1%) individuals a NNRTI. Raltegravir and maraviroc were initiated in 24 (12.5%) and 9 (4.7%) individuals. Ten [5.21%; 95% confidence interval (CI): 2.53%-9.37%] patients presented grade 3 TE, while 8 (4.17%; 95%CI: 1.82%-8.04%) subjects showed grade 4 TBE. No episodes of grade 4 TE or ART discontinuation due to hepatotoxic events were observed. The use of ritonavir-boosted atazanavir was the only independent predictor for grade 4 TBE [adjusted odds ratio: 7.327 (95%CI: 1.417-37.89); p = 0.018] in an analysis adjusted for age, sex and baseline HIV-RNA levels, while no factor could be independently associated with grade 3-4 TE.CONCLUSIONSCurrently, the frequency of severe ART-associated TE and TBE under real-life conditions in patients with chronic viral hepatitis is similar to what has been reported previously. However, episodes of grade 4 TE are less frequent and severe TE appears to be of lesser concern.
PB Public Library of Science
YR 2016
FD 2016-02-05
LK http://hdl.handle.net/10668/2221
UL http://hdl.handle.net/10668/2221
LA en
NO Neukam K, Mira JA, Collado A, Rivero-Juárez A, Monje-Agudo P, Ruiz-Morales J, et al. Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. PLoS ONE. 2015; 11(2):e0148104
NO Journal Article;
DS RISalud
RD Apr 5, 2025